SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)‘s stock had its “buy” rating reaffirmed by equities researchers at Maxim Group in a research report issued on Monday. They presently have a $14.00 price target on the specialty pharmaceutical company’s stock. Maxim Group’s price target would suggest a potential upside of 35.27% from the stock’s current price.
The analysts wrote, “SciClone is a US-based specialty pharma company with its operating focus on the China pharmaceuticals market.””
Shares of SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 0.49% on Monday, hitting $10.25. The stock had a trading volume of 307,761 shares. SciClone Pharmaceuticals has a one year low of $7.36 and a one year high of $15.02. The firm’s 50 day moving average is $9.76 and its 200-day moving average is $11.20. The stock has a market capitalization of $523.29 million, a PE ratio of 14.64 and a beta of 1.65.
In other news, Director Nancy T. Chang sold 25,040 shares of the company’s stock in a transaction on Tuesday, August 30th. The shares were sold at an average price of $10.30, for a total transaction of $257,912.00. Following the completion of the transaction, the director now directly owns 29,019 shares in the company, valued at $298,895.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Friedhelm Blobel sold 40,000 shares of the company’s stock in a transaction on Thursday, October 27th. The stock was sold at an average price of $9.30, for a total transaction of $372,000.00. Following the transaction, the chief executive officer now owns 126,784 shares of the company’s stock, valued at $1,179,091.20. The disclosure for this sale can be found here. Insiders own 7.63% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. GWM Advisors LLC bought a new position in shares of SciClone Pharmaceuticals during the third quarter valued at about $104,000. Mason Street Advisors LLC bought a new stake in SciClone Pharmaceuticals during the second quarter worth $127,000. Acrospire Investment Management LLC increased its stake in SciClone Pharmaceuticals by 190.0% in the third quarter. Acrospire Investment Management LLC now owns 12,782 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 8,375 shares during the last quarter. Aperio Group LLC increased its stake in SciClone Pharmaceuticals by 14.7% in the third quarter. Aperio Group LLC now owns 13,183 shares of the specialty pharmaceutical company’s stock worth $135,000 after buying an additional 1,690 shares during the last quarter. Finally, Rational Advisors LLC bought a new stake in SciClone Pharmaceuticals during the second quarter worth $140,000. Institutional investors own 75.68% of the company’s stock.
About SciClone Pharmaceuticals